Physician profile

David M Rubin

Optometrist · Venice, FL

NPI 1982682423

$9,257.28

in general payments reported to CMS, 2019-2025

37 companies · $2,751 in 2025

The $2,751 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,042.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,518.34 2022-2025 Lumigan, Durysta, Alphagan P
Bausch & Lomb Americas INC. $948.23 2023-2025 Miebo, Xiidra, Scoutpro Osmolarity System
Sun Pharmaceutical Industries INC. $585.75 2019-2025 Cequa
Tarsus Pharmaceuticals, INC. $527.33 2024-2025 Xdemvy
Alcon Vision LLC $470.55 2019-2025 Tryptyr, Precision7, Clareon
Notal Vision, INC. $457.02 2022-2025 Foresee Home
Sight Sciences, INC. $450.81 2021-2025 Omni Surgical System, Tearcare System
Amgen INC. $417.65 2024-2025 Tepezza
Coopervision INC. $307.25 2019-2024 Misight Contact Lens
Dompe US, INC. $270.66 2025 Oxervate
Eyevance Pharmaceuticals LLC $258.56 2019-2022
Alimera Sciences, INC. $250.98 2021-2024 Iluvien, Yutiq
Allergan, INC. $245.54 2019-2022
Aerie Pharmaceuticals, INC. $232.08 2019-2021
Harrow Eye, LLC $217.73 2024-2025 Vevye
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Apellis Pharmaceuticals, INC. $194.87 2023-2025 Syfovre
Bausch & Lomb, A Division of Bausch Health US, LLC $194.46 2019
Horizon Therapeutics Plc $182.79 2023 Tepezza
Ani Pharmaceuticals, INC. $162.27 2023-2025 Purified Cortrophin Gel, Yutiq
Maculogix, INC. $141.11 2019
Novartis Pharmaceuticals Corporation $135.06 2019-2023
Glaukos Corporation $133.76 2025 Kxl System (Not Refurbished), Idosetr
Eyepoint US, INC. $126.78 2021
Spark Therapeutics, INC. $121.85 2021
Janssen Biotech, INC. $103.95 2025 Tremfya
Coherus Oncology, INC. $101.66 2023-2024
Optovue, INC. $92.59 2019
Rxsight INC $87.92 2021
Kala Pharmaceuticals, INC. $81.53 2021-2022
Astellas Pharma US INC $51.64 2023-2024 Izervay
Sandoz INC. $44.58 2024 Cimerli
Regeneron Healthcare Solutions, INC. $32.29 2023 Eylea Hd
Biotissue Holdings INC. $31.17 2019-2024
Oyster Point Pharma, INC. $24.61 2025 Ryzumvi, Tyrvaya
Heidelberg Engineering, INC. $18.48 2025 Spectralis
Oasis Medical, INC. $18.24 2021
Mallinckrodt Hospital Products INC. $17.19 2024 Acthar

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$1,950.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David M Rubin

$9,257.28

in general payments reported 2019-2025

Years
2019-2025
Top company
Notal Vision, INC.
Context
The $2,751 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).

https://glasscript.com/doctor/44795/david-m-rubin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.